Delivering neoantigen mRNA/DNA or tumor antigen peptides for the manufacture of in vitro DC vaccines or for in vivo targeted DC delivery, driving potent, tumor-specific Cytotoxic T-Lymphocyte (CTL) responses.
Targeted Drug Delivery for DC based Immunotherapy
Dendritic cells (DCs) are the unrivaled antigen-presenting cells (APCs), acting as the immune system's "commanders" to initiate and guide T-cell responses. DC therapy, maximizing antigen presentation efficiency, is key to specific, long-lasting immune memory. Creative Biolabs provides targeted delivery system development, focusing on solving core challenges: efficient antigen loading, maturation, and activation for novel cancer and infectious disease vaccines.
What is Targeted Delivery?
In DC immunotherapy, targeted delivery means the highly selective and efficient delivery of antigens (peptides, nucleic acids) and adjuvants directly to DC cells. The focus is twofold: Antigen presentation optimization ensures cargo is effectively taken up by DCs and shunted into MHC class I and II presentation pathways to activate CD8+ and CD4+ T cells. Synergistic maturation signaling ensures the delivery vector simultaneously provides potent activation signals, inducing DCs to express high levels of co-stimulatory molecules (like CD80/CD86), thereby achieving full DC maturation essential for a robust CTL response.
Applications for DC-Based Immunotherapy
Novel Cancer Vaccines (Personalized Cancer Vaccines)
DC Function Enhancement & Maturation
Delivering maturation signaling molecules (such as TLR agonists and cytokine mRNA) to enhance the immune activation capacity of DCs, often co-delivered with antigens for superior outcome.
In vivo targeted DC Vaccines
Developing sophisticated nanocarrier systems that specifically recognize receptors on the surface of DCs (e.g., Nucleolin, XCR1) to directly deliver antigens and adjuvants to DC cells in lymph nodes.
Anti-infectious & Prophylactic Vaccines
Delivering pathogen antigens by designing in vitro DC vaccines or in vivo DC-targeted delivery systems to induce a robust protective immune response against viruses and bacteria.
Fig.1 The XCL1-XCR1 axis for targeted delivery of antigens to cDC1s.1
Delivery Challenges of DC-Based Immunotherapy
Low antigen presentation efficiency Insufficient DC maturation & activation Efficiency of non-viral gene modification
DC cells require highly efficient antigen uptake and successful transport to the endosome or cytoplasm for effective MHC class I/II presentation, a process often limited by endosomal sequestration and degradation.
What We Can Offer
We offer professional targeted delivery technologies, focusing on solving efficiency, maturation, and activation challenges in DC therapy manufacturing:
High-Efficiency Antigen Loading Platform
Our optimized LNP/nanogel carriers are specifically designed for nucleic acid (mRNA/DNA) antigen delivery, ensuring high-efficiency antigen expression in DC cells and rapid entry into the MHC presentation pathway for potent cross-priming.
DC Maturation-Induced Co-delivery
We specialize in the co-delivery of antigens and potent adjuvants (TLR agonists or co-stimulatory molecule mRNA), ensuring effective activation of DCs while loading antigens, which is critical for inducing a strong CD8+ T cell response.
In vivo DC-Targeting Nanocarriers
We develop sophisticated nanocarriers with surface-modified DC-specific ligands, including Nucleolin and XCR1 targeting peptides, to achieve precise antigen delivery to key DC subsets (cDC1s) in lymph nodes in vivo, eliminating the need for ex vivo isolation and culture.
Simplified Process and Scalability
Our non-viral delivery solutions can be seamlessly integrated into automated DC manufacturing processes, reducing operational steps, minimizing batch-to-batch variability, and lowering overall cost for clinical development.
Why Choose Us?
Targeted Precision
Expertise in next-generation ligands like Nucleolin and XCR1 for optimal cross-presenting cDC1 targeting.
End-to-End Solutions
Integrated LNP/nanogel platform for both in vitro manufacturing and in vivo targeted delivery.
Commercial-Ready
Scalable, automated synthesis protocols that minimize variability and accelerate clinical timelines.
Scientific Rigor
Deep knowledge in DC immunology and endosomal escape mechanisms to maximize antigen presentation efficiency.
Workflow
Ready to enhance your therapeutic candidate? Explore how our targeted immuno-matrix platform can custom-engineer your next-generation DC vaccine. Contact our technical advisory team today.
Reference
- Matsuo, Kazuhiko, et al. "Recent progress in dendritic cell-based cancer immunotherapy." Cancers 13.10 (2021): 2495. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers13102495.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
